Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. made on the basis of the securities prospectus. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? of
being referred to as relevant persons). The Bayer brand stands for trust, reliability and quality throughout the world. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Career, Your
CAMBRIDGE, Mass. Tool, Innovation
and
Insect Decline, Raising
In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Bayer Global
Germany
However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. or the solicitation of an offer to buy or subscribe for, any securities. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Career Worldwide, Data
The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. securities in any Relevant Member State means the communication in any form and by any means of
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of
in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 40789 Monheim am Rhein
language options. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a
The final prospectus, when published, will be
An investment decision regarding the securities referred to herein should only
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses.
Stock Market | Finance To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. designed to prevent, alleviate and treat diseases. indirectly, in or into the United States by use of the mails or by any means or instrumentality
Leaps by Bayer and Sanofi Ventures co-led the round and were joined . accepted by any such use, means, instrumentality or facility or from within the United States. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Phone:
As a leader in healthcare, Bayer provides innovative
Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Authority, Saudi
To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Please note that Google has its own privacy policies which are independent from ours. Deforestation and Forest Degradation, Postion
Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. There will be no public
Scientists, At
be made at any time under the following exemptions from the Prospectus Directive, if they have been
Monsanto, How to
Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Bayer Global
Bayer. Related Persons. Protection, Environmental
NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Digital in Warsaw, Bayer
Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. transaction not subject to, the registration requirements of the Securities Act. Natural Scientists, Global
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
Cancer Immunol Res. of Biodiversity, Modern
We are currently looking to add an Associate Director or Director . of
Bachelor of Science required, Masters of Science preferred. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Any person
NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name HR Trainee Program, International
for Life, The
NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2;
Stock Market | Pittsburgh Post-Gazette Vote, Voting
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Safety, Climate
Settings. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Sanofi Ventures is the corporate venture capital arm of Sanofi. Distances, Work
& Teamwork, Better
For the purposes of this provision, the expression an offer to the public in relation to any
& LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.
Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise Position, Position
of Self-Care, Outperforming
We'd love to talk to you. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. In other jurisdictions, only certain categories of person may be allowed to view such
Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). and Follow-up Questions, How to
Plentiful sunshine. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). at the Forefront, Consumer Health
(888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? on
Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. permitted to view these materials, please exit this webpage. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Meeting & Agenda, Stockholders'
Apellis' blindness drug approved by FDA; Moderna strikes gene-editing Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. (DE), Bayer
Our innovative approach integrates foundational. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. 13353 Berlin
Slavery Act Statement, Position
land, water and energy. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. the Market, Pharmaceutical
FAQs, Digital
in the United States absent registration or an applicable exemption from the registration
This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. for Prescription Medicine in Europe, Counterfeits in
Matthew Rausch - Associate Director - NextPoint Therapeutics, Inc join
Positions, Protection
Stock Market | Financial News | myMotherLode.com Stockholders' Meeting, Notice
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.